Deutsche Bank’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $48.1M | Sell |
365,345
-2,599
| -0.7% | -$345K | 0.02% | 635 |
|
|
2025
Q4 | $52.2M | Sell |
367,944
-82,860
| -18% | -$12M | 0.02% | 618 |
|
|
2025
Q3 | $63.3M | Buy |
450,804
+40,826
| +10% | +$5.53M | 0.02% | 562 |
|
|
2025
Q2 | $51.5M | Sell |
409,978
-16,956
| -4% | -$1.94M | 0.02% | 600 |
|
|
2025
Q1 | $47.2M | Sell |
426,934
-34,848
| -8% | -$4.41M | 0.02% | 631 |
|
|
2024
Q4 | $63M | Buy |
461,782
+23,951
| +5% | +$2.96M | 0.02% | 582 |
|
|
2024
Q3 | $50.4M | Buy |
437,831
+4,724
| +1% | +$648K | 0.02% | 598 |
|
|
2024
Q2 | $59.6M | Buy |
433,107
+73,251
| +20% | +$10M | 0.03% | 513 |
|
|
2024
Q1 | $49.6M | Buy |
359,856
+22,780
| +7% | +$3.11M | 0.02% | 555 |
|
|
2023
Q4 | $44.4M | Buy |
337,076
+59,776
| +22% | +$6.88M | 0.02% | 566 |
|
|
2023
Q3 | $31.2M | Sell |
277,300
-80,189
| -22% | -$8.44M | 0.02% | 587 |
|
|
2023
Q2 | $33.7M | Buy |
357,489
+17,284
| +5% | +$1.69M | 0.02% | 618 |
|
|
2023
Q1 | $34.4M | Sell |
340,205
-345,315
| -50% | -$35.9M | 0.02% | 616 |
|
|
2022
Q4 | $81.9M | Buy |
685,520
+269,065
| +65% | +$31.5M | 0.05% | 372 |
|
|
2022
Q3 | $44.2M | Sell |
416,455
-30,979
| -7% | -$3.14M | 0.03% | 519 |
|
|
2022
Q2 | $43.6M | Buy |
447,434
+33,960
| +8% | +$3.13M | 0.02% | 550 |
|
|
2022
Q1 | $38.8M | Buy |
413,474
+471
| +0.1% | +$39.9K | 0.02% | 665 |
|
|
2021
Q4 | $35.2M | Sell |
413,003
-16,655
| -4% | -$1.53M | 0.02% | 690 |
|
|
2021
Q3 | $41.2M | Buy |
429,658
+2,455
| +0.6% | +$232K | 0.02% | 674 |
|
|
2021
Q2 | $41.6M | Sell |
427,203
-61,403
| -13% | -$5.89M | 0.02% | 660 |
|
|
2021
Q1 | $47.5M | Buy |
488,606
+49,521
| +11% | +$5.19M | 0.03% | 606 |
|
|
2020
Q4 | $42.1M | Sell |
439,085
-69,910
| -14% | -$6.75M | 0.03% | 569 |
|
|
2020
Q3 | $48.9M | Sell |
508,995
-393,169
| -44% | -$45.5M | 0.03% | 453 |
|
|
2020
Q2 | $110M | Buy |
902,164
+29,917
| +3% | +$3.31M | 0.08% | 229 |
|
|
2020
Q1 | $75.5M | Sell |
872,247
-109,243
| -11% | -$10.7M | 0.07% | 277 |
|
|
2019
Q4 | $105M | Buy |
981,490
+86,768
| +10% | +$9.08M | 0.07% | 292 |
|
|
2019
Q3 | $80.6M | Sell |
894,722
-9,419
| -1% | -$880K | 0.06% | 346 |
|
|
2019
Q2 | $76.3M | Sell |
904,141
-120,494
| -12% | -$9.89M | 0.04% | 427 |
|
|
2019
Q1 | $90.3M | Buy |
1,024,635
+189,878
| +23% | +$15.9M | 0.05% | 381 |
|
|
2018
Q4 | $59.6M | Sell |
834,757
-92,095
| -10% | -$8.82M | 0.04% | 449 |
|
|
2018
Q3 | $114M | Buy |
926,852
+142,723
| +18% | +$16.2M | 0.06% | 350 |
|
|
2018
Q2 | $77M | Sell |
784,129
-212,814
| -21% | -$19M | 0.04% | 488 |
|
|
2018
Q1 | $82.7M | Buy |
996,943
+28,738
| +3% | +$2.43M | 0.04% | 459 |
|
|
2017
Q4 | $75.1M | Sell |
968,205
-480,975
| -33% | -$32.8M | 0.05% | 404 |
|
|
2017
Q3 | $88.8M | Buy |
1,449,180
+590,160
| +69% | +$31.1M | 0.06% | 354 |
|
|
2017
Q2 | $39.5M | Sell |
859,020
-28,714
| -3% | -$1.39M | 0.03% | 624 |
|
|
2017
Q1 | $38.4M | Buy |
887,734
+39,549
| +5% | +$1.69M | 0.03% | 616 |
|
|
2016
Q4 | $32.8M | Sell |
848,185
-175,010
| -17% | -$7.92M | 0.03% | 636 |
|
|
2016
Q3 | $51.8M | Sell |
1,023,195
-239,896
| -19% | -$11.9M | 0.04% | 517 |
|
|
2016
Q2 | $57.4M | Buy |
1,263,091
+354,316
| +39% | +$16.3M | 0.04% | 467 |
|
|
2016
Q1 | $35.9M | Sell |
908,775
-58,416
| -6% | -$2.32M | 0.03% | 633 |
|
|
2015
Q4 | $54.7M | Sell |
967,191
-68,327
| -7% | -$3.47M | 0.04% | 496 |
|
|
2015
Q3 | $41.2M | Buy |
1,035,518
+31,591
| +3% | +$1.53M | 0.03% | 548 |
|
|
2015
Q2 | $47.9M | Sell |
1,003,927
-49,647
| -5% | -$2.11M | 0.03% | 554 |
|
|
2015
Q1 | $41.8M | Buy |
1,053,574
+47,153
| +5% | +$1.69M | 0.03% | 595 |
|
|
2014
Q4 | $22.5M | Buy |
1,006,421
+53,051
| +6% | +$1.01M | 0.01% | 944 |
|
|
2014
Q3 | $14.9M | Buy |
953,370
+111,004
| +13% | +$1.66M | 0.01% | 1104 |
|
|
2014
Q2 | $12.5M | Buy |
842,366
+105,483
| +14% | +$1.49M | 0.01% | 1230 |
|
|
2014
Q1 | $11.9M | Sell |
736,883
-319,694
| -30% | -$5.47M | 0.01% | 1238 |
|
|
2013
Q4 | $9.87M | Sell |
1,056,577
-332,739
| -24% | -$3.25M | 0.01% | 1347 |
|
|
2013
Q3 | $15.7M | Buy |
1,389,316
+211,547
| +18% | +$2.91M | 0.01% | 1026 |
|
|
2013
Q2 | $15.8M | Buy |
+1,177,769
| New | +$14.5M | 0.01% | 976 |
|
Other funds holding NBIX
VPM
VCM
Deutsche Bank's NBIX Position: Q1 2026 in Review
Deutsche Bank reduced its Neurocrine Biosciences (NBIX) stake by 0.71% in Q1 2026, selling an estimated $345K and leaving 365,345 shares worth $48.1M. The position accounts for 0.02% of the portfolio, ranked #635.
Deutsche Bank first reported a position in NBIX in Q2 2013 and has held it in 52 quarters since. The position peaked at $114M in Q3 2018. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Deutsche Bank held 365,345 shares of Neurocrine Biosciences worth $48.1M as of Q1 2026.
- Deutsche Bank sold 2,599 Neurocrine Biosciences shares in Q1 2026, an estimated $345K.
- Neurocrine Biosciences made up 0.02% of Deutsche Bank's portfolio in Q1 2026, its #635 holding.
- Deutsche Bank first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 52 quarters since.
- Deutsche Bank's Neurocrine Biosciences position peaked at $114M in Q3 2018.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.